CTLA4 and cancer: To the Editor: Immune checkpoint inhibitors (ICIs), including programmed death receptor-1 (PD-1), programmed death ligand-1 (PD-1L), and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) inhibitors, have significantly advanced cancer treatment by enhancing host antitumor immune responses.1